Thomas Pietschmann heads the Institute for Experimental Virology at TWINCORE. He completed his biology studies at the University of Würzburg and Duke University (Durham, NC, USA) in 1996. In 2000, he completed his doctorate at the Institute of Virology at the University of Würzburg on mechanisms of viral morphogenesis in retroviruses and joined Professor Ralf Bartenschlager's group at the Institute of Virology in Mainz as a postdoc. In 2002, he moved to the Department of Molecular Virology at the University of Heidelberg together with Bartenschlager. There, Thomas Pietschmann established an Emmy Noether junior research group focussing on the morphogenesis and entry mechanism of the hepatitis C virus.
In spring 2007, he and his research group were appointed to TWINCORE. Thomas Pietschmann is an elected member of the Scientific Advisory Board of the Society of Virology and the DFG Review Board 204 (Microbiology, Virology and Immunology). He is spokesperson for the DZIF Hannover/Braunschweig site and the "Infection Research" research programme of the Helmholtz Centre for Infection Research.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
We are investigating how antibodies protect against HCV infection, in particular what properties they have during a healing infection. The aim is to identify antibodies that are important for an effective vaccine against HCV.
The project investigates the factors that determine the species barrier mechanism of HCV and make it impossible to study the infection in animal models. The aim is to use genetic screening systems to develop in vivo models for vaccine research.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
Jumde R, Jézéquel G, Saramago M, Frank N, Adam S, Cunha M, Bader C, Gunesch A, Köhler N, Johannsen S, Bousis S, Pietschmann T, Matos R, Müller R, Arraiano C, Hirsch A
Reichert I, Lee J, Weber L, Fuh M, Schlaeger L, Rößler S, Kinast V, Schlienkamp S, Conradi J, Vondran F, Pfaender S, Scaturro P, Steinmann E, Bartenschlager R, Pietschmann T, Heeren J, Lauber C, Vieyres G
Haid S, Matthaei A, Winkler M, Sake S, Gunesch A, Milke V, Köhler N, Rückert J, Vieyres G, Kühl D, Nguyen T, Göhl M, Lasswitz L, Zapatero-Belinchón F, Brogden G, Gerold G, Wiegmann B, Bilitewski U, Brown R, Brönstrup M, Schulz T, Pietschmann T
OPERA research project launched to further develop antiviral active substances
Research team from Bochum and Hannover shows that the hepatitis E virus also attacks organs other than the liver
Hannover researchers develop stem cell-based infection model
